Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen

MeSH terms

• Antibodies, Monoclonal, Murine-Derived / administration & dosage*
• Antibodies, Monoclonal, Murine-Derived / adverse effects
• Disease Progression
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Male
• Pulmonary Fibrosis / drug therapy*
• Pulmonary Fibrosis / etiology
• Risk Assessment
• Rituximab
• Scleroderma, Systemic / complications
• Scleroderma, Systemic / diagnosis*
• Scleroderma, Systemic / drug therapy*
• Severity of Illness Index
• Treatment Outcome